NCT03473691 2024-12-09
Breast50
University of Virginia
Phase EARLY_PHASE1 Withdrawn
Clinical Trials
8 trialsNCT02487979 2022-01-18
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02302339 2019-09-06
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Celldex Therapeutics
Phase 2 Terminated
NCT02713828 2019-07-16
PrE0504
PrECOG, LLC.
Phase 1/2 Terminated
NCT01997333 2019-03-08
METRIC
Celldex Therapeutics
Phase 2 Completed
NCT03326258 2018-07-18
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT03067935 2018-05-21
Individual Patient Expanded Access-Glembatumumab Vedotin
Celldex Therapeutics
No longer available
NCT01156753 2017-07-02
EMERGE
Celldex Therapeutics
Phase 2 Completed